Zydus Lifesciences Launches Biosimilar Nivolumab in India
Filing Summary
Zydus Lifesciences Ltd has introduced the world’s first biosimilar of Nivolumab, branded as Tishtha™, in India as of January 22, 2026. The biosimilar is available in 100 mg and 40 mg dosages, priced at ₹28,950 and ₹13,950, respectively. This pricing is approximately one-fourth of the reference drug, aiming to reduce treatment costs for cancer patients. The launch is expected to benefit over 500,000 patients. Tishtha™ is developed and manufactured in India, reinforcing Zydus’s capabilities in advanced biologics and Immuno-Oncology.
Zydus Lifesciences Ltd has launched the world’s first biosimilar of Nivolumab, named Tishtha™, in India on January 22, 2026. This product is available in 100 mg and 40 mg dosages, priced at ₹28,950 and ₹13,950, respectively. The pricing strategy makes Tishtha™ approximately one-fourth the cost of the reference drug, aiming to improve affordability for patients undergoing cancer treatment.
The introduction of Tishtha™ is expected to benefit more than 500,000 patients in India. The biosimilar is designed to reduce the overall treatment burden by offering a cost-effective alternative to existing therapies. The two-strength portfolio allows oncologists to optimize dosing and minimize wastage, which is a significant factor in treatment economics for immunotherapy.
Zydus has developed and manufactured Tishtha™ in India, ensuring long-term dependability for patients. The availability of this biosimilar aims to provide consistent and predictable access to advanced Immuno-Oncology treatment. The company emphasizes the importance of reliable access to checkpoint inhibitors for cancer patients who require therapy over multiple cycles.
Zydus Lifesciences Ltd is an innovation-led life-sciences company with a global presence across pharmaceuticals and consumer wellness. The company is supported by an emerging MedTech franchise and operates in markets including the United States and India. Zydus employs 29,000 people worldwide, including 1,500 scientists engaged in research and development. The company focuses on unlocking new possibilities in life sciences through quality healthcare solutions.